Maxcyte (MXCT) Capital Expenditures (2020 - 2026)

Maxcyte (MXCT) has 7 years of Capital Expenditures data on file, last reported at $72000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 88.97% year-over-year to $72000.0 in Q1 2026; TTM through Mar 2026 was $143000.0, a 81.74% decrease from a year earlier, with the FY2025 full-year figure at $724000.0, up 646.39% from the prior year.
• Capital Expenditures for Q1 2026 stood at $72000.0, up from -$200000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for MXCT reached as high as $17.6 million in Q4 2022 and fell as low as -$5.4 million in Q2 2022.
• Historically, Capital Expenditures has averaged $1.2 million across 5 years, with a median of $72000.0 in 2026.
• Across the five-year window, Capital Expenditures surged 12118.94% in 2022 and sank 595.56% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $17.6 million in 2022, then sank by 112.61% to -$2.2 million in 2023, then soared by 102.79% to $62000.0 in 2024, then plunged by 422.58% to -$200000.0 in 2025, then surged by 136.0% to $72000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $72000.0 in Q1 2026, -$200000.0 in Q4 2025, and -$313000.0 in Q3 2025.